Efecte Plc Launches a New Employee Share Savings Plan
EFECTE PLC -- COMPANY ANNOUNCEMENT – 1 March 2023 at 9:00 am
EFECTE PLC LAUNCHES A NEW EMPLOYEE SHARE SAVINGS PLAN
The Board of Directors of Efecte Plc has decided to establish an Employee Share Savings Plan (ESSP) for the employees of Efecte Plc and its subsidiaries.
The aim of the ESSP is to encourage employees to acquire and own Efecte shares, and it is intended to align the interests of the shareholders and the employees as well as to increase employees’ motivation and long-term commitment to the company.
The ESSP consists of annually commencing plan periods, each one comprising of a 12-month savings period and a holding period following the savings period. The ESSP is offered to approximately 200 Efecte employees. The employees will have an opportunity to save a proportion of their salaries and invest those savings in Efecte shares. The savings will be used for acquiring Efecte shares twice a year after the publication dates of the respective half-year reports. The Board decides if the savings shares are purchased from the market or if the savings shares are delivered to the participants by a directed share issue decided separately by the Board. As a reward for the commitment, Efecte grants the participating employees a gross award of one matching share for each savings share acquired with their savings. Continuity of employment and holding of acquired savings shares for the duration of the holding period are the prerequisites for receiving the award.
The potential award will be settled in shares, or partly in shares and partly in cash, after the end of the holding period. The cash proportion is intended to cover taxes and tax-related costs arising from the award in those countries where the employer has the obligation to withhold taxes. Matching shares will be freely transferable after their registration on the participant’s book-entry account. Any dividends to be paid on the acquired savings shares, the matching shares given within the ESSP, and any other shares received within the ESSP will be reinvested in additional shares on the next potential acquisition date. These shares will have an equal right to matching shares.
Participation in the ESSP is voluntary and the employees will be invited to participate in one plan period at a time. The first savings period will commence on 1 April 2023 and end on 31 March 2024. The holding period of the first plan period begins at the first acquisition of savings shares and ends on 31 March 2026. The maximum number of matching shares (gross number before taxes) for the first plan period is approximately 63,836, calculated at prevalent share price. The final number of matching shares depends on the employees’ participation and savings rate in the plan, and the fulfilment of the prerequisites for receiving matching shares, as well as the number of shares acquired from the market with savings.
Head of Legal
+358 400 383 064
Evli Plc, tel +358 40 579 6210
Efecte helps people digitalize and automate their work. Customers across Europe leverage our cloud service to operate with greater agility, to improve the experience of end-users, and to save costs. The use cases for our solutions range from IT service management and ticketing to improving employee experiences, business workflows, and customer service. We are the European Alternative to the global goliaths in our space. Our headquarters is located in Finland and we have regional hubs in Germany, Poland and Sweden. Efecte is listed on the Nasdaq First North Growth Market Finland marketplace.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ordinær generalforsamling21.3.2023 16:13:06 CET | pressemeddelelse
Indkaldelse til ordinær generalforsamling den 21. april 2023 er vedhæftet. Vedhæftet fil 10-2023 Indklad OGF 2023
Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities21.3.2023 16:00:00 CET | Press release
Company Announcement No. 16/2023 Copenhagen, 21 March 2023 Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a) Name Niels Frederiksen 2. Reason for the notification a) Position/title CEO and member of the Executive Management b) Initial notification/amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Scandinavian Tobacco Group A/S b) LEI code 5299003KG4JS99TRML67 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Shares DK0060696300 – STG b) Nature of the transaction Grant of shares due to vesting of performance share
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation21.3.2023 15:48:10 CET | Press release
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulation Sandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the US Food and Drug Administration (FDA) approved a citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz® (adalimumab-adaz) injection. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira®* (adalimumab), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.1 Sandoz
Articles of Association for RTX A/S21.3.2023 15:28:54 CET | Press release
Nørresundby, Denmark, 21 March 2023 Announcement no. 11/2023 Articles of Association for RTX A/S as adopted at the Annual General Meeting on 26 January 2023 and finally adopted at the extraordinary general meeting on 10 March 2023 (cf. company announcement 10/2023) has been registered and published. The Articles of Association are available at the company’s website www.rtx.dk under: Governance => Articles of Association. Questions and further information: CEO Peter Røpke, tel: +45 96 32 23 00 Attachment RTX A-S - Articles of Association 10 March 2023
Vedtægter for RTX A/S21.3.2023 15:28:54 CET | pressemeddelelse
Nørresundby, den 21. marts 2023 Selskabsmeddelelse nr. 11/2023 Vedtægter for RTX A/S som vedtaget på RTX’s ordinære generalforsamling 26. januar 2023 og endeligt vedtaget på selskabets ekstraordinære generalforsamling 10. marts 2023 (jf. selskabsmeddelelse 10/2023) er blevet registreret og offentliggjort. Vedtægterne er tilgængelige på selskabets hjemmeside www.rtx.dk under: Governance => Vedtægter. Spørgsmål og yderligere oplysninger: CEO Peter Røpke, tlf: +45 96 32 23 00. Vedhæftet fil RTX A-S - vedtægter pr. 10. marts 2023